ArticleMolecular neurobiology2025
Oxymatrine Alleviates Cerebral Ischemia/Reperfusion Injury By Targeting HDAC1 to Regulate Mitochondria-Related Autophagy and Oxidative Stress.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SUMOylation in Mitochondrial Quality Control: Mechanisms and Implications for Neurodegenerative Disease.Molecular neurobiology · 2026Review
- Cerebral Ischemia-Reperfusion Injury: Unraveling the Mitophagy-Oxidative Stress Axis for Neuroprotective Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Oxymatrine (OMT), a major alkaloid extracted from Sophora flavescens, has been widely recognized for its anti-inflammatory and anti-cancer properties. However, its precise neuroprotective mechanisms in cerebral ischemia/reperfusion (I/R) injury remain to be fully elucidated. In this study, we combined in vivo and in vitro models to investigate the therapeutic effects of OMT on cerebral I/R injury and glutamate-induced neuronal toxicity during the reperfusion process. In vivo, a mouse middle cerebral artery occlusion (MCAO) model was established to recapitulate I/R injury, whereas glutamate-exposed HT22 hippocampal neurons were utilized as an in vitro model to mimic excitotoxic damage. Bioinformatics analysis, integrated with molecular docking, identified histone deacetylase 1 (HDAC1) as a potential direct target of OMT. Subsequent experimental validation demonstrated that OMT attenuates I/R-induced brain damage by modulating HDAC1-mediated pathways involved in autophagy and oxidative stress regulation. OMT treatment significantly reduced infarct volume and improved neurological function in mice. At the cellular level, OMT suppressed mitochondrial apoptosis and reactive oxygen species (ROS) accumulation, restored mitochondrial membrane integrity, and rebalanced mitochondrial dynamics by downregulating fission-related proteins (Fis1) and upregulating fusion markers (Mfn2). Additionally, OMT inhibited excessive autophagy through modulation of the PINK1/Parkin signaling pathway, as evidenced by decreased expression of LC3-II/I ratio, PINK1, Parkin, and NBR1, along with restored levels of P62.These findings suggest that OMT exerts its neuroprotective effects in cerebral I/R injury by targeting HDAC1, thereby alleviating oxidative stress and excessive autophagy. This study provides new mechanistic insights and supports OMT as a promising therapeutic candidate for ischemic stroke treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.